Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Articles|May 7, 2010
New industrial rotary evaporator from Büchi Labortechnik AG
New industrial rotary evaporator from Büchi Labortechnik AG.
Advertisement
After 10 successful years on the market, the 20 liter Rotavapor® R-220 from Buchi is ready for an upgrade. Changed requirements from the market led to the development of the new Rotavapor® R-220 SE (Second Edition), providing the latest technology.
The design of the Rotavapor® R-220 SE focuses on safety and easy handling, as the proven Buchi philosophy is still true: Easy handling is a key factor for safe operation. The patented flask fixation and the EasyClamp enable a fast and safe installation of the glass parts and the clearly arranged design of the control panels reduces the risk of operating errors.An optional shield protects the instrument in rough environments.
A variety of new tools and features make the Rotavapor® ready for the future:
- A USB module enables to record the process data to a memory stick.
- A level sensor allows to supervise the receiving flask, so that the instrument is stopped as soon as the flask is full.
- USB and RS485 interfaces provide for the control of system components like vacuum pump or recirculating chiller.
The large and bright 6” display provides all information about the distillation process. The large high-contrast digits indicating the bath-, vapor- and cooling temperature as well as the rotation speed are clearly visible, also from a distance.
An integrated vacuum controller guarantees reproducible and stable conditions and the wide choice of 7 different glass configurations enable to adapt the instrument for almost any application.
Advertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
What the Olanzapine Depot Approval Means for CMC Teams
3
Complying with International Pharmacopoeias
4
Q&A: Patient-Centric Drug Development Should Start at Product Definition
5